+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmacoepidemiology and Pharmacovigilance. Synergistic Tools to Better Investigate Drug Safety

  • Book

  • October 2018
  • Elsevier Science and Technology
  • ID: 4398669

Pharmacoepidemiology and Pharmacovigilance: Synergistic Tools to Better Investigate Drug Safety examines the role of pharmacoepidemiologic studies in drug development and its use as a prevention tool in pharmacovigilance activities. The book introduces the various epidemiologic tools and study designs commonly used for the surveillance of drug-related adverse effects and reviews the strengths and weaknesses of each. Criticisms surrounding pharmacoepidemiologic research and issues that often interfere or complicate the conduct and interpretation of these studies are also explored. Case studies illustrate the passive and active surveillance of adverse drug reactions in clinical situations, covering important pharmacoepidemiologic concepts like health risk management and safety.

The book helps pharmaceutical industry groups engaged in drug safety, clinical investigators, medical evaluators and those seeking regulatory approval enhance the safety of the drug development process for all patient populations.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Introduction 2. The role of pharmacoepidemiologic research in drug development 3. Pharmaco-epidemiology in the prevention of adverse drug reactions 4. Case Studies


Sabrina Nour Pre-Market Scientific Evaluator and Epidemiologist, Health Canada, Montreal, Canada. Sabrina Nour is a Clinical Evaluator and Epidemiologist where she is in charge of reviewing the efficacy and safety of biological products. She holds a Master's degree in epidemiology and a certificate in population risk evaluation and health management. Sabrina has acquired more than 6 years of experience working on drug safety and pharmacovigilance, including pharmacoepidemiology. Her major interests lie in pharmacoepidemiology methodology, pharmacovigilance activities, and in the influence of health policies on populations. Gilles Plourde Senior Clinic Evaluator for Health Canada's regulatory agency; Associate Professor, Department of Clinical Pharmacology and Physiology, University of Montreal, Canada and Associate Professor, School of Physical Activity Science, University of Ottawa, Canada. Dr. Plourde is a senior clinic evaluator for the Health Canada's regulatory agency. He is an associate professor in the department of clinical pharmacology and physiology, Faculty of Medicine at the University of Montreal and at the school of physical activity sciences, Faculty of Health Sciences at the University of Ottawa. He holds a doctorate in medicine (MD) from the University of Montreal and a PhD in experimental medicine from Laval University. His studies led him to publish several articles in highly rated peer-reviewed journals and to make numerous presentations for prestigious national and international associations. He has more than 12 years' experience working on drug safety, especially for biologic products involved in the treatment of various cancers. He has also supervised many students and employees interested in the prevention of the adverse effects of health products both in clinical research and/or when health products have obtained marketing authorization.